Madrigal Pharmaceuticals, Inc.
MASH-focused biopharma anchored by commercial Rezdiffra and an expanding combination-development strategy.
Metabolic / liver disease (MASH) · Oral THR-beta agonist & RNAi combination strategies · Commercial + Phase 3
MASH-focused biopharma anchored by commercial Rezdiffra and an expanding combination-development strategy.
Metabolic / liver disease (MASH) · Oral THR-beta agonist & RNAi combination strategies · Commercial + Phase 3